Research
Hormonal
High doses of n-3 omega fatty acids (1.8 g/day) may accelerate heart rate and increase the risk of ventricular tachycardia or fibrillation in patients with existing ventricular arrhythmias.
If you have a history of ventricular tachycardia or fibrillation, avoid high-dose fish oil supplements (1.8g/day or more) unless explicitly approved by your cardiologist, as they may worsen your condition.
ModerateRefutesMEDIUM confidence
In their randomised controlled trial involving 200 patients, 1.8 g daily fish oil supplementation caused significantly important accelerations of the heart beat in patients with ventricular tachycardia (VT)... and ventricular fibrillation (VF), a heart failure due to sudden cardiac death.
Why this rating
Based on a single RCT cited (Raitt et al., 2005), requiring further studies for definitiveness.
Source
n‐3 Omega fatty acids: a review of current knowledge
Uğur Göğüş et al. · International Journal of Food Science & Technology · 2010
DOI 10.1111/j.1365-2621.2009.02151.x
narrative_reviewCited 358×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- n-3 omega fatty acids reduce inflammation by inhibiting the production of pro-inflammatory eicosanoids (PGE2, TXA2, LTB4) and promoting anti-inflammatory eicosanoids (PGE1, PGI3, LTB5).Strong
- Daily intake of 1-3 grams of n-3 omega fatty acids (EPA/DHA) reduces cardiovascular risk by lowering serum triglycerides and LDL cholesterol, and inhibiting platelet aggregation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →